Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma

• Published in: Cancer reports 2024-04, Vol.7 (4), p.e2042-n/a
• Main Authors: Ohama, Hideko, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Hatanaka, Takeshi, Tani, Joji, Takaguchi, Koichi, Atsukawa, Masanori, Itobayashi, Ei, Nishimura, Takashi, Tsuji, Kunihiko, Tajiri, Kazuto, Ishikawa, Toru, Yasuda, Satoshi, Toyoda, Hidenori, Fukunishi, Shinya, Ogawa, Chikara, Kakizaki, Satoru, Shimada, Noritomo, Naganuma, Atsushi, Kawata, Kazuhito, Kosaka, Hisashi, Kuroda, Hidekatsu, Matono, Tomomitsu, Yata, Yutaka, Ochi, Hironori, Tada, Fujimasa, Nouso, Kazuhiro, Morishita, Asahiro, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Tsutsui, Akemi, Nagano, Takuya, Yokohama, Keisuke, Nishikawa, Hiroki, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Iijima, Hiroko, Kaibori, Masaki, Hiasa, Yoichi, Kumada, Takashi
• Format: Article
• Language: English
• Subjects: atezolizumab plus bevacizumab; CRAFITY score; hepatocellular carcinoma; IMABALI score; IMABALI‐De score; modified albumin‐bilirubin grade; prognosis
• ISSN: 2573-8348; 2573-8348
• DOI: 10.1002/cnr2.2042

Aims The aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment. Methods A total of 719 patients (males 577, median age 74 years) treated with Atez/Bev between September 2020 and January 2023 were enrolled. Factors related to overall survival (OS) were extracted and a prognostic scoring system based on hazard ratio (HR) was created. OS and progression‐free survival (PFS) were retrospectively examined, and the prognostic ability of the newly developed system was compared to CRAFITY score using concordance index (c‐index) and Akaike information criterion (AIC) results. Results Cox‐hazards multivariate analysis showed BCLC classification C/D (HR 1.4; 1 point), AFP ≥100 ng/mL (HR 1.4; 1 point), mALBI 2a (HR 1.7; 1 point), mALBI 2b/3 (HR 2.8; 2 points), and DCP ≥100 mAU/mL (HR 1.6; 1 point) as significant factors. The assigned points were added and used to develop the IMmunotherapy with AFP, BCLC staging, mALBI, and DCP evaluation (IMABALI‐De) scoring system. For IMABALI‐De scores of 0, 1, 2, 3, 4, and 5, OS was not applicable (NA), NA, 26.11, 18.79, 14.07, and 8.32 months, respectively (p